Featured Research

from universities, journals, and other organizations

New strategy to avoid collateral damage in cancer

Date:
May 27, 2014
Source:
Institute of Molecular Biotechnology
Summary:
Scientists have identified the final component that turns the RNA ligase into a fully viable enzyme in humans. That opens up perspectives for new treatment strategies for numerous types of breast cancer and leukemia. Ligases are enzymes that aid the bonding of two molecules. For example, the RNA ligase ensures that copied parts of DNA are bonded into a viable tRNA, which in turn delivers the blueprint for producing proteins.

Scientists at IMBA have identified the final component that turns the RNA ligase into a fully viable enzyme in humans. That opens up perspectives for new treatment strategies for numerous types of breast cancer and leukemia.

Ligases are enzymes that aid the bonding of two molecules. For example, the RNA ligase ensures that copied parts of DNA are bonded into a viable tRNA, which in turn delivers the blueprint for producing proteins.

New starting point for cancer treatment

RNA ligases also have other functions that have not yet been researched in depth in humans because the composition of this important enzyme was not clear. "We already know from studies on yeasts that ligases are involved in defending cells from stress factors," said Javier Martinez, a group leader at IMBA. These functions are highly probable in mammal cells as well, and could be a new starting point for cancer therapies -- especially for the treatment of various types of breast cancer and leukemia. Scientists already believe there is a close relationship between the function of the enzyme and the onset of these diseases.

"If we target and block one part of the ligase function, we will be able to approach cancer therapy in a much more specific manner than before. The impact of this enzyme is much farther down the cell's signal transduction cascade than conventional medicinal targets," said Martinez. This can be compared to a tree with one leaf affected by a disease. Of course it would be possible to cut off a thick limb to get rid of the diseased leaf. But it would be far less damaging to the tree to cut off just one thin branch.

This new approach is highly promising. But first Javier Martinez wants to test the function of ligases in mice.

Fundamental component of biology identified

This research into the function of ligases and their role in fighting cancer was made possible by the work of Martinez' team, in which the entire composition of ligase was resolved piece by piece. The researchers' initial success came in 2011, when they were first able to describe the most important basic components of the enzyme (Popow et al., Science 2011). Now Johannes Popow has achieved a breakthrough, which the journal Nature has published in its current issue.

He discovered that an important protein called archease is bonded to the ligase. Without this protein, the enzyme can catalyze only one single bonding process. Archease is what makes it possible for the enzyme to regenerate so it is ready for the next catalyzation process. Popow is very pleased "that we have identified this crucial component, and that by understanding the composition of ligase we will now be able to examine the function of this important enzyme more closely, and possibly apply the results for medical science."


Story Source:

The above story is based on materials provided by Institute of Molecular Biotechnology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Johannes Popow, Jennifer Jurkin, Alexander Schleiffer, Javier Martinez. Analysis of orthologous groups reveals archease and DDX1 as tRNA splicing factors. Nature, 2014; DOI: 10.1038/nature13284

Cite This Page:

Institute of Molecular Biotechnology. "New strategy to avoid collateral damage in cancer." ScienceDaily. ScienceDaily, 27 May 2014. <www.sciencedaily.com/releases/2014/05/140527101115.htm>.
Institute of Molecular Biotechnology. (2014, May 27). New strategy to avoid collateral damage in cancer. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2014/05/140527101115.htm
Institute of Molecular Biotechnology. "New strategy to avoid collateral damage in cancer." ScienceDaily. www.sciencedaily.com/releases/2014/05/140527101115.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins